HPS2-THRIVE: High myopathy risk with niacin/laropiprant

Extended-release niacin and laropiprant added to simvastatin were associated with a significantly increased risk of definite myopathy. Interestingly, the risk of myopathy was significantly higher in randomized patients from China than in patients from Europe.

http://www.theheart.org/article/1511869.do

Source: theHeart.org - February 27, 2013 Category: Cardiology Source Type: news